Evolocumab is named as an intervention in 12 current clinical trials in our China and USA registers. 8 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is General Hospital of Shenyang Military Region (2). The most-studied condition is Acute Myocardial Infarction.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Acute Myocardial Infarction | 2 |
| Hypercholesterolemia | 1 |
| Acute Ischemic Stroke | 1 |
| Cardiovascular Disease | 1 |
| Myocardial Infarction | 1 |
| Stroke | 1 |
| Coronary Revascularization | 1 |
| Hypertriglyceridemia Induced Acute Pancreatitis | 1 |
| Coronary | 1 |
| Coronary Artery Disease | 1 |
| Intracranial Artery Stenosis | 1 |
| Stroke, Ischemic | 1 |
| Atherosclerosis, Cerebral | 1 |
| Myocardial Ischaemic Syndrome | 1 |
| Coronary Heart Disease | 1 |
| Ischemic Stroke | 1 |
| Large-Artery Atherosclerosis (Embolus/Thrombosis) | 1 |
| Acute Coronary Syndromes | 1 |
| Lead sponsor | Trials |
|---|---|
| General Hospital of Shenyang Military Region | 2 |
| Yun Dai Chen | 2 |
| Regeneron Pharmaceuticals | 1 |
| Shanghai Tong Ren Hospital | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| Amgen | 1 |
| West China Hospital | 1 |
| Nanjing First Hospital, Nanjing Medical University | 1 |
| Nanjing Medical University | 1 |
| Tongji Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 10 | 7 |
| Clinical trials in USA | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
12 current trials in our China and USA registers name Evolocumab (also registered as PCSK9 inhibitor) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 8 of the 12 trials are recruiting: 7 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
General Hospital of Shenyang Military Region (2), Yun Dai Chen (2), Regeneron Pharmaceuticals (1) and Shanghai Tong Ren Hospital (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Evolocumab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Evolocumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Evolocumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.